US4452791A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
Assignee: ER Squibb and Sons LLC
•
Filing: 1982-03-15
•
Granted: 1984-06-05
•
Expires: 2002-03-15
Abstract
Abstract Compounds of the structure ##STR1## are provided which are inhibitors of angiotensin converting enzyme and are useful in the treatment of hypertension.
Inventors
- 👤 Denis E. Ryono
- 👤 Edward W. Petrillo, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 18:14
CPC Classifications
C; C07; C07D; C07D209/00; C07D209/02; C07D209/44; C07D209/48; A; A61; A61P; A61P43/00; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/30; C07F9/306; C07F9/32; C07F9/3205; C07F9/3211; C07F9/3223; C07F9/3241; C07F9/3258; C07F9/3288; C07F9/48; C07F9/4808; C07F9/4816; C07F9/547; C07F9/553; C07F9/5537; C07F9/572; C07F9/5728; C07F9/576; C07F9/59; C07F9/645; C07F9/6503; C07F9/6506; C07F9/655; C07F9/65515; C07F9/6553; C07F9/655345; C07F9/6558; C07F9/6561; C07F9/65615
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
430 words
A compound of the formula ##STR309## and pharmaceutically acceptable salts thereof, wherein R 1 is lower alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, furyl, furylalkyl, thienyl, thienylalkyl, pyridyl, pyridylalkyl or ##STR310## and R 5 and R 6 are independently selected from hydrogen, lower alkyl, haloalkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl furyl, furylalkyl, thienyl, thienylalkyl, pyridyl or pyridylalkyl; R 2 and R 4 each is independently hydrogen, lower alkyl, arylalkyl, benzhydryl or ##STR311## wherein R 7 is hydrogen, lower alkyl or phenyl, R 8 is hydrogen, lower alkyl, lower alkoxy or phenyl or R 7 and R 8 taken together are --(CH 2 ) 2 --, --(CH 2 ) 3 --, --CH═CH--, or ##STR312## n is 0 or 1; R 3 is NH 2 (CH 2 ) m --, ##STR313## R 9 is hydrogen, lower alkyl, aryl or arylalkyl, and m is 0 or an integer of from 1 to 5, and --XOR 4 is an imino or amino acid derivative of the formula ##STR314## R 10 is hydrogen, lower alkyl, halogen, keto, hydroxy, ##STR315## a 1- or 2-naphthyl of the formula ##STR316## a 1- or 2-naphthyloxy of the formula ##STR317## or a 1- or 2-naphthylthio of the formula ##STR318## R 11 is keto, halogen, ##STR319## --O--lower alkyl, a 1- or 2-naphthyloxy of the formula ##STR320## or a 1- or 2-naphthylthio of the formula ##STR321## R 12 is keto or ##STR322## R 13 is halogen or --Y--R 23 ; R 20 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl; R 21 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy; m 1 is 0 or an integer from 1 to 5; p is 1, 2 or 3 provided that p is more than 1 only if R 20 or R 21 is hydrogen, methyl, methoxy, chloro, or fluoro; R 22 is hydrogen or lower alkyl of 1 to 4 carbons; Y is oxygen or sulfur; R 23 is lower alkyl of 1 to 4 carbons, ##STR323## or the R 23 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di(lower alkyl of 1 to 4 carbons) substituent; R 18 is lower alkyl, benzyl, or phenethyl; and R 19 is hydrogen, lower alkyl, benzyl or phenethyl.
Claim 2
Dependent Claim
430 words
A compound of the formula ##STR309## and pharmaceutically acceptable salts thereof, wherein R 1 is lower alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, aminoalkyl, furyl, furylalkyl, thienyl, thienylalkyl, pyridyl, pyridylalkyl or ##STR310## and R 5 and R 6 are independently selected from hydrogen, lower alkyl, haloalkyl, aryl, alkylaryl, cycloalkyl, cycloalkylalkyl furyl, furylalkyl, thienyl, thienylalkyl, pyridyl or pyridylalkyl; R 2 and R 4 each is independently hydrogen, lower alkyl, arylalkyl, benzhydryl or ##STR311## wherein R 7 is hydrogen, lower alkyl or phenyl, R 8 is hydrogen, lower alkyl, lower alkoxy or phenyl or R 7 and R 8 taken together are --(CH 2 ) 2 --, --(CH 2 ) 3 --, --CH═CH--, or ##STR312## n is 0 or 1; R 3 is NH 2 (CH 2 ) m --, ##STR313## R 9 is hydrogen, lower alkyl, aryl or arylalkyl, and m is 0 or an integer of from 1 to 5, and --XOR 4 is an imino or amino acid derivative of the formula ##STR314## R 10 is hydrogen, lower alkyl, halogen, keto, hydroxy, ##STR315## a 1- or 2-naphthyl of the formula ##STR316## a 1- or 2-naphthyloxy of the formula ##STR317## or a 1- or 2-naphthylthio of the formula ##STR318## R 11 is keto, halogen, ##STR319## --O--lower alkyl, a 1- or 2-naphthyloxy of the formula ##STR320## or a 1- or 2-naphthylthio of the formula ##STR321## R 12 is keto or ##STR322## R 13 is halogen or --Y--R 23 ; R 20 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, hydroxy, phenyl, phenoxy, phenylthio, or phenylmethyl; R 21 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy; m 1 is 0 or an integer from 1 to 5; p is 1, 2 or 3 provided that p is more than 1 only if R 20 or R 21 is hydrogen, methyl, methoxy, chloro, or fluoro; R 22 is hydrogen or lower alkyl of 1 to 4 carbons; Y is oxygen or sulfur; R 23 is lower alkyl of 1 to 4 carbons, ##STR323## or the R 23 groups join to complete an unsubstituted 5- or 6-membered ring or said ring in which one or more of the carbons has a lower alkyl of 1 to 4 carbons or a di(lower alkyl of 1 to 4 carbons) substituent; R 18 is lower alkyl, benzyl, or phenethyl; and R 19 is hydrogen, lower alkyl, benzyl or phenethyl.
Claim 3
Dependent Claim
11 words
The compound as defined in claim 1 wherein n is 0.
Claim 4
Dependent Claim
11 words
The compound as defined in claim 1 wherein n is 1.
Claim 5
Dependent Claim
23 words
The compound as defined in claim 1 wherein R 3 is NH 2 (CH 2 ) m wherein m is 2 to 5.
Claim 6
Dependent Claim
12 words
The compound as defined in claim 1 wherein R 1 is arylalkyl.
Claim 7
Dependent Claim
12 words
The compound as defined in claim 1 wherein X--OR 4 is ##STR324##
Claim 8
Dependent Claim
14 words
The compound as defined in claim 6 wherein R 4 is H or benzyloxy.
Claim 9
Dependent Claim
11 words
The compound as defined in claim 1 having the name (±)-1-[5-amino-2-[hydroxy-(4-phenylbutyl)phosphinyl]-1-oxopentyl]-L-proline.
Claim 10
Dependent Claim
13 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]methyl]-1-oxohexyl]-L-proline, benzyl ester.
Claim 11
Dependent Claim
14 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[hydroxy (4-phenylbutyl)phosphinyl]methyl]-1-oxohexyl]-L-proline, dilithium salt.
Claim 12
Dependent Claim
11 words
The compound as defined in claim 1 having the name (±)-1-[6-acetylamino-2-[[[hydroxy(4-phenylbutyl)phosphinyl]methyl]-1-oxohexyl]-L-proline.
Claim 13
Dependent Claim
13 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phosphinyl]methyl]-1-oxohexyl]-L-proline, (2,2-dimethyl-1-oxopropoxy)methyl ester.
Claim 14
Dependent Claim
13 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[hydroxy(2-phenylethyl)phosphinyl]methyl]-1-oxohexyl]-L-proline, dilithium salt.
Claim 15
Dependent Claim
25 words
A composition useful for treating hypertension comprising a pharmaceutically acceptable carrier and a hypotensive agent as defined in claim 1 or pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
21 words
The method of alleviating hypertension in a mammalian specie which comprises administering an effective amount of the composition of claim 14.
Claim 17
Dependent Claim
11 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[[(2,2-dimethyl-1-oxopropoxy)methoxy](4-phenylbutyl)phosphinyl]methyl]-1-oxohexyl]-L-proline.
Claim 18
Dependent Claim
17 words
The compound as defined in claim 1 having the name (±)-1-[6-amino-2-[[[(2,2-dimethyl-1-oxopropoxy)methoxy](4-phenylbutyl)phosphinyl]methyl]hexyl]-L-proline, (2,2-dimethyl-1-oxopropoxy)methyl ester, 4-methylbenzenesulfonic acid (1:1) salt.
References Cited (Backward Citations)
US4053651A
Cited
US4199512A
Cited
US4105776A
Cited
US4192878A
Cited
BE868532A
Cited
EP0000833A1
Cited
US4151172A
Cited
US4129566A
Cited
US4154935A
Cited
GB2027025A
Cited
GB2028327A
Cited
EP0009183A1
Cited
US4316896A
Cited
US4168267A
Cited
US4256751A
Cited
GB2039478A
Cited
US4217359A
Cited
GB2048863A
Cited
US4234489A
Cited
US4303583A
Cited
US4310461A
Cited
US4316905A
Cited
US4337201A
Cited
US4379146A
Cited
US4374131A
Cited
US4381297A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-06-05 | 1987-12-05 | 1988-06-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-06-05 | 1991-12-05 | 1992-06-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-06-05 | 1995-12-05 | 1996-06-05 | $7700.00 | Window Closed / Lapsed |